Pegloticase efficacy and safety in kidney transplant recipients; results of the phase IV, open-label PROTECT clinical trial.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical transplantation"
DOI: 10.1111/ctr.14993
Abstract: INTRODUCTION Kidney transplant (KT) recipients have a high prevalence and severity of gout. Pegloticase (pegylated recombinant uricase) rapidly metabolizes serum uric acid (sUA), and its efficacy is not impacted by kidney function. METHODS This open-label,… read more here.
Keywords: gout; kidney; efficacy; kidney transplant ... See more keywords
AB0867 Pegloticase re-treatment after a gap in therapy: data from two phase iii trials and an open-label extension study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.5365
Abstract: Background Pegloticase is a PEGylated recombinant uricase approved in the US for treating adult patients with chronic refractory gout. As a biologic medication, pegloticase is administered intravenously every 2 weeks. It is currently not known… read more here.
Keywords: gap; infusion; treatment; pegloticase ... See more keywords
THU0416 PEGLOTICASE RESPONSE IMPROVEMENT BY CO-TREATMENT WITH METHOTREXATE: RESULTS FROM THE MIRROR OPEN-LABEL CLINICAL TRIAL IN PATIENTS WITH UNCONTROLLED GOUT
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.3932
Abstract: Gout is a painful inflammatory arthritis caused by persistently elevated serum uric acid (sUA) levels. Pegloticase, an infused recombinant PEGylated uricase, rapidly lowers sUA levels by converting uric acid to allantoin, a water-soluble molecule that… read more here.
Keywords: infusion; treatment; pegloticase; horizon therapeutics ... See more keywords